Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with a five-fold increase in ischemic stroke risk. Approximately 90% of thrombi in non-valvular AF originate from the left atrial appendage (LAA). Left atrial appendage closure (LAAC) has emerged as an alternative strategy to oral anticoagulation for stroke prevention in selected patients. Objective: To evaluate the efficacy, safety, procedural outcomes, and long-term clinical benefits of LAAC in patients with atrial fibrillation at elevated risk of thromboembolic events. Methods: A comprehensive review and synthesis of contemporary clinical evidence, randomized controlled trials, registries, and observational studies were conducted. Outcomes assessed included stroke incidence, systemic embolism, major bleeding, procedural success, and mortality. Results: Major randomized trials demonstrated that LAAC is non-inferior to warfarin for prevention of stroke and systemic embolism. Procedural success rates exceed 95% in contemporary practice. Significant reductions in hemorrhagic stroke and major bleeding have been reported during long-term follow-up. Device-related complications continue to decline with advancements in technology and operator experience. Conclusion: LAAC represents a safe and effective stroke prevention strategy for appropriately selected patients with atrial fibrillation, particularly those with contraindications to long-term anticoagulation.